Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
C Degirolamo, C Sabbà, A Moschetta - Nature reviews Drug discovery, 2016 - nature.com
C Degirolamo, C Sabbà, A Moschetta
Nature reviews Drug discovery, 2016•nature.comThe endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for
maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism,
modulation of vitamin D and phosphate homeostasis and metabolic adaptation during
fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array
of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and
cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF …
maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism,
modulation of vitamin D and phosphate homeostasis and metabolic adaptation during
fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array
of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and
cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF …
Abstract
The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.
nature.com
